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Abstract: Objective: The aim of this study was to determine the 1-year mortality risk subsequent to Contrast-Induced 
Nephropathy (CIN) following CECT imaging, relative to other well-recognized predictors of mortality. Methods: We 
followed a prospective, consecutive cohort of ambulatory patients who received intravenous contrast for CECT for the 
outcome of death from any cause within 1 year. In a multivariate analysis, we compared CIN with other predictors of 
mortality: active malignancy, coronary artery disease (CAD), congestive heart failure (CHF) and age ≥70 years. 
Anticipating that terminal cancers would account for the majority of deaths in this population, we also analyzed the subset 
of patients without an active malignancy at the time of enrollment. Results: We followed 633 patients and 46 died (7%, 
95%CI: 5-9%) within 1 year. The incidence of CIN was 11% (95%CI: 8-14%). Active malignancy (HR 9.2, 95%CI: 5.1-
16.8), CIN (HR 2.4, 95%CI: 1.3-4.6), CHF (HR 2.1, 95%CI: 1.0-4.2), CAD (HR 2.2, 95%CI: 1.0-5.5) and age ≥70 years 
(HR 1.8, 95%CI: 1.0-3.8) were significant predictors of all-cause mortality. Among patients without active malignancies, 
the mortality rate was 4% (25/580, 95%CI: 3-6%) and CIN (HR 4.0, 95%CI: 1.7-9.6) and age ≥70 years (HR 3.7, 95%CI: 
1.4-9.7) were significantly associated with death, whereas CAD (HR 2.5, 95%CI: 0.8-7.7) and CHF (HR 1.8, 95%CI: 0.6-
5.3) were not. Conclusions: The development of CIN following CECT is associated with an increased likelihood of death at 
1 year among patients with and without active malignancies, comparable to CAD, CHF and advanced age. 
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1. Introduction
Expert guidelines define contrast induced nephropathy 
(CIN) as a 25% relative increase or 0.5mg/dL absolute 
increase in serum creatinine value, measured 2-7 days after 
exposure to iodinated contrast.[1, 2] The clinical 
significance of CIN remains controversial, especially in the 
setting of intravenous contrast after contrast enhanced 
computed tomography (CECT).[3, 4] Most outcome studies 
of CIN have been conducted in patients exposed to intra-
arterial contrast coronary angiography.[1, 5] Despite an 
exponential increase in persons receiving intravenous 
iodinated contrast material for CECT in United States,[6] to 
the best of our knowledge, no study has reported long-term 
outcomes in the population undergoing CECT. 
We have recently published data from a prospective, 
cohort study of over 600 patients who received intravenous 
contrast for CECT for a range of indications in the 
outpatient setting. Patients were followed for the 
development of CIN and for short-term outcomes (45-days 
following contrast exposure) including severe renal failure 
and death from renal failure.[7] Notably, this was a 
heterogeneous population with a low overall risk for CIN 
and severe outcomes; only 10% of this population had 
preexisting renal insufficiency (estimated glomerular 
filtration rate [eGFR] <60ml/min/1.73m
2
)[8] and 51% were 
discharged directly to the outpatient setting following 
evaluation CECT. We found that CIN occurred in 11% of 
patients and was associated with a marked increased risk of 
severe renal failure and death from renal failure at 45-days 
(relative risk 48, 95% CI: 8 to 302).[7] The objectives of 
the present study were to measure the outcomes of CIN and 
subsequent 1-year mortality, and to test if CIN was an 
independent predictor of 1-year mortality in this cohort, 
after adjusting for other well-recognized predictors of 
mortality. 
2. Methods
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2.1. Study design 
This was a prospective, observational cohort study, 
conducted at a single-center aimed at documenting the 
incidence of CIN and death at 1-year. This study was 
approved by the institutional review board and written 
informed consent was obtained from study participants. 
2.2. Study Setting 
Patients were enrolled from the emergency department 
(ED) of Carolinas Medical Center in Charlotte, NC: an 
urban, academic center with over 900 beds and the ED 
staffed by board-certified emergency medicine physicians 
24/7. Over 110,000 patients are treated in this ED annually. 
CECT imaging studies were performed on 2 Multi-Detector 
Siemens Somatom Sensation 64-slice scanners (Siemens 
Medical Solutions USA, Inc, Malvern, PA) and interpreted, 
in real-time, by on-site, board certified radiologists. All 
patients received Iopamidol-370 (Isovue-370®, Bracco 
Diagnostics, Princeton, NJ). The institution also utilizes a 
centralized medical record system for 25 hospitals and over 
100 primary and specialty practice locations, allowing the 
follow-up of a large, ambulatory population for outcomes, 
with reasonable reliability.[7, 9] 
2.3. Selection of Participants 
The methods of enrollment have been previously 
described.[7, 9] Briefly, we enrolled consecutive patients 
undergoing CECT. Exclusion criteria included: 1) age <18 
years, 2) hemodialysis or peritoneal dialysis within 45 days 
prior to enrollment or documented prior physician-directed 
plans to start dialysis within 45-days after enrollment, 3) 
kidney transplant prior to or planned at the time of 
enrollment, 4) intravenous contrast for any reason within 
14 days prior to enrollment, 5) pregnancy or post-partum 
<48 hours, 6) patients with immediately life threatening 
injuries as classified by the institutional guidelines, 7) the 
inability to provide written, informed consent, or 8) patient-
stated unavailability for the follow-up blood draw. Patients 
that were enrolled, but did not receive contrast (e.g., the 
study was canceled or changed to a non-contrasted study 
after the patient was enrolled) were also excluded. 
2.4. Study Protocol 
The methods of data collection have been published 
previously.[7] Briefly, patients were enrolled at the time an 
order was placed by the ED provider for a CECT of any 
body-region (Centricity®, GE Healthcare, Chalfont St. 
Giles, UK). Data included the presence or absence of risk 
factors for 1-year mortality at the bedside, in real-time 
through a combination of patient interview, review of the 
ED chart and provider interview. Using standard 
phlebotomy techniques, we collected blood at the time of 
enrollment and at least 48 hours but not more than 169 
hours (2 to 7 days) following contrast administration for 
serum creatinine measurements (i-STAT, Abbott Point of 
Care, Inc; East Windsor, NJ). 
2.5. Outcome Determination 
The primary outcome of this study was defined as death 
from any cause within 1-year of the enrollment CECT. We 
used a rigorous, sequential, and redundant approach, 
executed in the following order: 1) A telephone interview 
with the patient or next of kin, 2) An explicit search of the 
medical record for evidence of death, and 3) A search of the 
Social Security Death Index (SSDI).[7, 9] For telephone 
follow-up, failure was declared after five 5 separate 
attempts made at different times on different days of the 
week over a two week period. We also reviewed the 
electronic medical record for all participants, starting at 2-
years post-enrollment, to serve as a confirmatory (in the 
event of telephone success) or primary method (in event of 
telephone failure). Finally, we conducted a search of the 
social security death index for patients whose status could 
not be determined by either telephone interview or 
electronic medical record review. Discrepancies were 
resolved using a blinded adjudication process requiring the 
consensus of 2 out of 3 independent evaluators.[7] 
2.6. Data Analysis 
With the 1-year mortality rate as the dependent variable, 
we used a Cox regression multivariate survival analysis to 
determine the hazard ratios (HRs) for the independent 
variables of 1) CIN; 2) Age ≥70 years at the time of 
enrollment; 3) coronary artery disease (CAD), determined 
by patient report of a prior myocardial infarction or 
physician-determined narrowing of the coronary arteries 
requiring medical or surgical intervention; 4) congestive 
heart failure (CHF) ,defined by a patient report of a 
physician-determined diagnosis requiring therapy and the 
presence of CHF recorded by the provider in the medial 
chart at the time of enrollment; and 5) active malignancy, 
defined as the presence of a malignancy with ongoing or 
planned physician-directed chemotherapy, radiation, and/or 
surgical treatment as reported by the patient or recorded in 
the medical chart at the time of enrollment. Conditions 
identified subsequent to the index visit were not considered 
a part of the study-definition for independent variables. For 
example, patients with a malignancy diagnosed after the 
index visit were classified as cancer-free in our analysis. 
Anticipating that deaths attributable to terminal cancers 
would account for the majority of deaths observed within a 
population undergoing CECT imaging studies, we also 
performed a separate analysis of the subset of patients 
without a history of active malignancy at the time of study 
enrollment. 
Finally, the baseline serum creatinine measurement and 
patient characteristics were also used to determine the 
prevalence of baseline renal insufficiency defined as an 
eGFR <60 mL/min/1.73m
2
 calculated using the 
Modification in Diet in Renal Disease (MDRD) equation.[8] 
We report overall outcome incidence, population 
characteristics and presumptive risk factors as proportions 
with associated 95% confidence intervals (95%CI) 
calculated using the Clopper-Pearson method. We 
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performed all statistical analyses using STATSDirect V3.3 
software (Chesire, UK). 
3. Results 
We followed 633 patients that received intravenous 
contrast for CECT in the ED, of which, 53/633 (8%, 95%CI 
6 to 11%) had an active malignancy identified at enrollment. 
Patient enrollment and outcomes are summarized in Fig. 1 
and population characteristics, including the prevalence of 
mortality risk-factors and literature-defined risk-factors for 
CIN at enrollment, are summarized in Table 1. Notably, 
only 10% of patients enrolled in this study had measurable 
baseline renal insufficiency, 17% had diabetes mellitus and 
approximately one-half were discharged from the 
emergency department following the CECT. The majority 
of CECT studies (571/633, 90% 95%CI 88 to 92%) were 
obtained for non-traumatic indications and imaging of the 
abdomen and/or pelvis accounted for over half of the CECT 
studies conducted (54%, 95%CI 50 to 58%) and174/633 
(27%, 24 to 31%) were pulmonary angiography studies.[7, 
10] 
 
Figure 1. Enrollment and selection of participants. 
The follow-up blood draw allowed the determination of 
CIN (presence or absence) in 431/633 patients (68%, 
95%CI: 64 to 72%), including 250 patients who were not 
inpatients at the time of follow-up. The majority of enrolled 
patients (603/633, 95%, 95%CI: 93 to 97%) reported that 
their primary access to follow-up care was within the CHS 
system and survival or death was definitively determined 
by a combination of telephone interview and medical 
record review for 553 patients (87%, 95%CI 85-90%). 
There were no discrepancies in the reporting of a death 
event from telephone interview and medical record review. 
Query of the SSDI identified 4 deaths, not previously 
identified by telephone interview and medical record 
review. 
Table 1. Clinical characteristics of study participants at enrollment. 
Enrollment  
Characteristics 
Unselected  
Cohort 
N = 633 
Subset  
Without 
Malignancy 
N = 58 
Female Gender, %  
(95%CI) 
57 (53 to 61) 56 (52 to 60) 
Caucasian, %  
(95%CI) 
40 (36 to 44) 39 (35 to 43) 
African American, %  
(95%CI) 
52 (48 to 56) 52 (48 to 56) 
Other/Unknown  
Race, % (95%CI) 
8 (6 to 11) 8 (6 to 11) 
Age ≥ 70 years, %  
(95%CI) 
7 (5 to 10) 7 (5 to 10) 
Active Malignancy, %  
(95%CI) 
8 (6 to 11) N/A 
Congestive 
 Heart  
Failure, %  
(95%CI) 
5 (3 to 7) 6 (4 to 8) 
Coronary Artery  
Disease, %  
](95%CI) 
7 (5 to 10) 5 (3 to 7) 
Hypertension, %  
(95%CI) 
44 (40 to 48) 43 (38 to 47) 
Diabetes Mellitus, % 
(95%CI) 
17 (15 to 21) 17 (14 to 21) 
Renal Insufficiency*, %  
(95%CI) 
10 (6 to 10) 9 (7 to 12) 
95%CI = 95% confidence interval. 
*Estimated glomerular filtration rate <60 mL/min/1.73m2. 
The outcome of CIN within one week was observed in 
70/633 patients (11%, 95%CI: 9 to 14%) and the outcome 
of mortality at one year was observed in 46/633 (7%, 
95%CI 5 to 9%) The one-year mortality rate after CIN was 
13/70 (18%) compared with 33/563 (6%) who did not 
develop CIN (risk ratio = 3.1, 95% CI 1.7 to 5.4). The 
multivariate Cox regression analysis revealed age ≥70 years 
(HR 1.8, 95%CI: 1.0-3.8), CAD (HR 2.2, 95%CI: 1.0-5.5), 
CHF (HR 2.1, 95%CI: 1.0-4.2), active malignancy (HR 9.2, 
95%CI: 5.1-16.8), and CIN (HR 2.4, 95%CI: 1.3-4.6) all as 
significant predictors of all-cause mortality (likelihood 
ration Χ2 = 59.9 df = 5 p<0.0001). Approximately one-half 
of patients (21/46, 46%, 95% 31 to 61%) who died within 
1-year of enrollment had active malignancy at enrollment. 
The all-cause mortality rate among cancer-free patients was 
4% (25/580, 95%CI: 3-6%). In this subset, the incidence of 
CIN remained unchanged: 11% (95% CI: 8 to 13%). Within 
this subset of cancer-free patients, CIN (HR 4.0, 95%CI: 
1.7-9.6) and age ≥70 years (HR 3.7, 95%CI: 1.4-9.7) were 
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significantly associated with death at 1-year, whereas CAD 
(HR 2.5, 95%CI: 0.8-7.7) and CHF (HR 1.8, 95%CI: 0.6-
5.3) were not (Χ2 = 18.2 df = 4 p = 0.0011). 
The adjusted cumulative hazard curves and proportional 
survival for mortality at one year, between CIN+ and CIN- 
patients for the unselected cohort and malignancy-free 
subset are shown in Figures 2a and 2b. 
 
(a) 
 
(b) 
Figure 2. a Adjusted cumulative hazard for 1-year mortality in the 
unselected cohort. CIN 11% (95%CI: 8 to 14%); 1-yr Mortality 7% (95% 
CI: 5 to 9%); Likelihood Ratio Χ2 = 59.9 df = 5 p<0.0001. b Adjusted 
cumulative hazard for 1-year mortality in the subset of patients without 
active malignancies at enrollment. CIN 11% (95%CI: 8 to 13%); 1-yr 
Mortality 4% (95% CI: 3 to 6%); Likelihood Ratio Χ2 = 18.2 df = 4 p = 
0.0011. 
4. Discussion 
In this prospective cohort of patients who were exposed 
to intravenous iodinated contrast for the purpose of CT 
imaging, CIN was a significant, independent risk factor for 
long-term mortality. The multivariate model found that CIN 
was comparable to advanced age or prior heart disease as a 
prognosticator for death within one year, and CIN remained 
a significant predictor of mortality even among patients 
without active malignancies. This increased risk of death 
after CIN was observed within a patients sample that might 
be considered low risk for acute kidney injury inasmuch as 
one-half of the cohort was discharged from the emergency 
department after the CECT scan, only 10% of patients had 
baseline renal insufficiency, and only 17% of patients had 
diabetes mellitus. In fact, we did not observe a significant 
difference in the incidence of CIN between patients 
hospitalized at enrollment (10%, 95%CI 7 to 13%) 
compared to those discharged directly from the emergency 
care setting (13%, 95%CI 9 to 17%). Strengths of this study 
include the patient sample, which was derived from a large, 
heterogeneous population enrolled prior to the following: 1) 
availability of outcomes results of the CECT; 2) all related 
treatment initiation; 3) the disposition decision from the 
emergency department (admission or discharge); and, of 
course, 4) the primary outcomes of CIN or death. We 
submit that that we executed a rigorous and demanding 
protocol to obtain the follow-up blood draw and mortality 
endpoints.[11] We were able to definitively determine 1-
year survival through telephone follow-up and/or definitive 
medical record review for 87% of our population, and 
query of the SSDI for the other 13%. 
These data provide a new perspective to existing 
literature as the first to demonstrate in the outpatient CECT 
population that 1) CIN is significantly associated with a 
severe outcome (death), observed over a long-term follow-
up period, and that 2) CIN remained a significant predictor 
even after adjustment for age, prior heart disease (coronary 
artery disease or CHF), or malignancy. The 
pathophysiology of CIN and the confounding effects of 
comorbidities have limited the ability to define a causative 
relationship between contrast exposure and outcomes of 
acute kidney injury (AKI) or death in the present and prior 
studies.[5, 12] Our data reinforce the notion that CIN has 
an indolent course that could easily go unrecognized, 
particularly in the ambulatory and emergency care settings, 
because of an absence of a protocol explicitly designed to 
compulsorily measure a repeat blood sample within the 2 to 
7 day follow-up period. Even with a blood sample in hand, 
clinicians lack a validated biological marker that directly 
indicates the presence of AKI from CIN. Instead, we must 
rely on serum creatinine, an indirect marker of glomerular 
filtration rate that has many well-known limitations as a 
biomarker for AKI.[13] Despite the inadequacies of 
creatinine, prior data demonstrates that AKI, from any 
cause, significantly contributes to long-term mortality and 
morbidity and our study is consistent with these data.[14-16] 
Ideally, the causative role of CIN would be established in 
a well-matched, unexposed control group. However, in real 
clinical practice, the indications for CECT inherently define 
a fundamentally different patient sample than would be 
obtained either from a population undergoing CT imaging 
without iodinated contrast, or not undergoing CT imaging 
at all. It would be ethically implausible to define a direct 
control group by experimentally withholding contrast for a 
CECT scan ordered as part of standard medical care. 
However, Solomon et al were able to compare the 
incidence of CIN and subsequent mortality in patients 
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enrolled in randomized of a trial designed to study the 
differential risk of CIN from low-osmolar versus iso-
osmolar contrast. In this study, a lower incidence of CIN 
was also associated with a significantly lower incidence of 
subsequent mortality at 1 –year. This study was limited to 
patients with multiple risk-factors for CIN including 
moderate to severe renal insufficiency, limiting a direct 
comparison to the unselected ambulatory population.[12] 
Similarly, the literature is replete with studies that 
demonstrate that an interval increase in serum creatinine 
following iodinated contrast exposure is strongly associated 
with subsequent development of severe renal failure and 
increased risk of mortality.[5] While the current state of the 
literature does not directly establish the causal role of CIN, 
our observed risk ratio for mortality of 3.1 is comparable to 
that observed with AKI from heterogeneous causes.[16] 
This study has several limitations. First, we enrolled 
patients only from a single, albeit, large academic center. 
Our study also excluded critically ill and injured patients, 
which accounted for approximately 20% of the overall ED 
patient population. As such, the results may not be 
generalizable to other populations. Second, this study 
required both an enrollment and follow-up blood draw and 
short- and long-term follow-up, which likely accounts for 
the 40% rate of at which eligible emergency department 
patients declined to participate. Similarly, 32% of patients 
did not complete the follow-up blood draw. However, 
approximately half of patients were discharged from the 
emergency department on the day of enrollment and 
another 22% of patients were discharged to the outpatient 
setting within 48 hours of contrast exposure. Finally, it is 
possible that the timing of the follow-up blood draw may 
not have captured the peak-creatinine level in some patients. 
The standard definition for CIN typically cites an interval 
serum creatinine level measured 48 to 72 hours after 
contrast exposure and 71% of our follow-up samples were 
obtained in this time frame.[7] However, current literature 
estimates that this restriction may miss up to 60% of CIN 
cases.[2, 17-21] Taken together, the overall effect of these 
limitations has likely resulted in an underestimation of both 
the incidence of CIN and resulting risk-association with 
mortality at one year. Thus, our results represent a 
conservative estimate of the association of CIN with long-
term mortality, which is likely to be greater than what we 
report in this study. 
In conclusion, the development of CIN following CECT 
in the ambulatory setting is associated with an increased 
risk of subsequent mortality over the following year, after 
adjusting for other well-recognized risk factors for 
mortality, including age ≥ 70 years, active malignancy, 
CAD and CHF. Among patients without active 
malignancies at the time of CECT, CIN and age ≥ 70 years 
remained significantly associated with 1-year mortality. 
These data implicate the need to test outcomes-based 
imaging protocols that limit exposure to intravenous 
iodinated contrast in the ambulatory and emergency care 
settings. 
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